Brief: Mustang Bio Announces First Patient Successfully Treated By Ex Vivo Lentiviral Gene Therapy To Treat Rag1 Severe Combined Immunodeficiency
27/07/2022 13:39
July 27 (Reuters) - Fortress Biotech Inc FBIO.O :
* MUSTANG BIO ANNOUNCES FIRST PATIENT SUCCESSFULLY TREATED
BY EX
VIVO LENTIVIRAL GENE THERAPY TO TREAT RAG1 SEVERE COMBINED
IMMUNODEFICIENCY
Source text for Eikon: ID:nGNX93DlKP
Further company coverage: FBIO.O
((Reuters.Briefs@thomsonreuters.com;))
Recent news on Mustang Bio
See all newsAdvisory: Alert on global oncology breakthroughs tagged to multiple pharma firms withdrawn
U.S. STOCKS ON THE MOVE-Dow, Phibro, Mustang Bio
Mustang soars on FDA's orphan drug tag for brain cancer therapy
Mustang Bio Inc reports results for the quarter ended December 31 - Earnings Summary
Brief: Mustang Bio Inc - Enters Sale And Surrender Agreement With Abbvie